Tanvex BioPharma Statistics

Total Valuation

Tanvex BioPharma has a market cap or net worth of TWD 11.24 billion. The enterprise value is 12.14 billion.

Market Cap	11.24B
Enterprise Value	12.14B

Important Dates

The next estimated earnings date is Friday, March 7, 2025.

Earnings Date	Mar 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Tanvex BioPharma has 164.07 million shares outstanding. The number of shares has increased by 18.34% in one year.

Current Share Class	n/a
Shares Outstanding	164.07M
Shares Change (YoY)	+18.34%
Shares Change (QoQ)	+3.39%
Owned by Insiders (%)	1.45%
Owned by Institutions (%)	5.37%
Float	96.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	247.03
PB Ratio	9.79
P/TBV Ratio	9.82
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-7.49
EV / Sales	296.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.80

Financial Position

The company has a current ratio of 2.62, with a Debt / Equity ratio of 1.43.

Current Ratio	2.62
Quick Ratio	2.18
Debt / Equity	1.43
Debt / EBITDA	n/a
Debt / FCF	-1.19
Interest Coverage	-27.31

Financial Efficiency

Return on equity (ROE) is -128.72% and return on invested capital (ROIC) is -32.66%.

Return on Equity (ROE)	-128.72%
Return on Assets (ROA)	-30.54%
Return on Capital (ROIC)	-32.66%
Revenue Per Employee	294,640
Profits Per Employee	-11.66M
Employee Count	139
Asset Turnover	0.01
Inventory Turnover	0.23

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.26% in the last 52 weeks. The beta is 0.46, so Tanvex BioPharma's price volatility has been lower than the market average.

Beta (5Y)	0.46
52-Week Price Change	+12.26%
50-Day Moving Average	65.25
200-Day Moving Average	57.83
Relative Strength Index (RSI)	61.28
Average Volume (20 Days)	160,978

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tanvex BioPharma had revenue of TWD 40.96 million and -1.62 billion in losses. Loss per share was -10.98.

Revenue	40.96M
Gross Profit	10.85M
Operating Income	-1.57B
Pretax Income	-1.62B
Net Income	-1.62B
EBITDA	-1.47B
EBIT	-1.57B
Loss Per Share	-10.98

Full Income Statement

Balance Sheet

The company has 742.10 million in cash and 1.65 billion in debt, giving a net cash position of -905.50 million or -5.52 per share.

Cash & Cash Equivalents	742.10M
Total Debt	1.65B
Net Cash	-905.50M
Net Cash Per Share	-5.52
Equity (Book Value)	1.15B
Book Value Per Share	7.00
Working Capital	578.42M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.28 billion and capital expenditures -97.27 million, giving a free cash flow of -1.38 billion.

Operating Cash Flow	-1.28B
Capital Expenditures	-97.27M
Free Cash Flow	-1.38B
FCF Per Share	-8.41

Full Cash Flow Statement

Margins

Gross Margin	26.49%
Operating Margin	-3,838.22%
Pretax Margin	-3,958.15%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Tanvex BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.34%
Shareholder Yield	-18.34%
Earnings Yield	-16.03%
FCF Yield	-12.28%

Stock Splits

The last stock split was on March 2, 2023. It was a reverse split with a ratio of 0.3335779572.

Last Split Date	Mar 2, 2023
Split Type	Reverse
Split Ratio	0.3335779572

Scores

Tanvex BioPharma has an Altman Z-Score of -5.12. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.12
Piotroski F-Score	n/a